Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Account Payables (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Change in Account Payables for 12 consecutive years, with -$75000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables rose 87.07% year-over-year to -$75000.0, compared with a TTM value of $2.0 million through Sep 2025, up 115.87%, and an annual FY2024 reading of -$537000.0, down 138.69% over the prior year.
  • Change in Account Payables was -$75000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $661000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.0 million in Q1 2025 and bottomed at -$757000.0 in Q2 2024.
  • Average Change in Account Payables over 5 years is $357000.0, with a median of $462000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables surged 1387.3% in 2021, then plummeted 1405.17% in 2024.
  • Year by year, Change in Account Payables stood at $477000.0 in 2021, then tumbled by 130.19% to -$144000.0 in 2022, then surged by 681.25% to $837000.0 in 2023, then plummeted by 174.79% to -$626000.0 in 2024, then skyrocketed by 88.02% to -$75000.0 in 2025.
  • Business Quant data shows Change in Account Payables for FENC at -$75000.0 in Q3 2025, $661000.0 in Q2 2025, and $2.0 million in Q1 2025.